(Q38020234)

27 August 2017

title

Anti-angiogenic drug discovery: lessons from the past and thoughts for the future (English)

1 reference

27 August 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

Jessie M Wu

1

1 reference

27 August 2017

Carolyn A Staton

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

21 June 2012

1 reference

Expert Opinion on Drug Discovery

27 August 2017

published in

1 reference

27 August 2017

volume

7

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

723-743

1 reference

Tumor angiogenesis: therapeutic implications

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Tumor dormancy in vivo by prevention of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Neuropilins in physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab for the treatment of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Normalization of the vasculature for treatment of cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Renal effects of anti-angiogenesis therapy: update for the internist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Targeted therapy of hepatocellular carcinoma: present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Experience with sorafenib and adverse event management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Tumor angiogenesis: pericytes and maturation are not to be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Tumour vascularization: sprouting angiogenesis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Stromal-epithelial interaction in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Clinical significance of vasculogenic mimicry in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Tumor cell plasticity and angiogenesis in human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Transdifferentiation of glioblastoma cells into vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Translating animal research into clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Development trends for new cancer therapeutics and vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Finding the tumor copycat: approximating a human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Initiating oncogenic event determines gene-expression patterns of human breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Finding the tumor copycat. Therapy fails, patients don't

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Design of clinical trials of radiation combined with antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

The angiogenic process as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Real-time imaging reveals the single steps of brain metastasis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Endpoints for assessing drug activity in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Issues in using progression-free survival when evaluating oncology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Clinical trial end points for high-grade glioma: the evolving landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Angiogenesis in pre-malignant conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Current status and future prospects for anti-angiogenic therapies in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Angiogenesis and current antiangiogenic strategies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Matrix metalloproteinases in tumorigenesis: an evolving paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Recurrent priapism related to oxaliplatin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Cloning, characterization and neuronal expression profiles of tumor endothelial marker 7 in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Genes that distinguish physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

PET Imaging of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.695774

10.1517/17460441.2012.695774

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference